A Possible Link Between Crohn's Disease and Ankylosing Spondylitis Via Klebsiella Infections

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2006 Aug 31

PMID 16941202

Citations 19

Authors

Alan Ebringer

Taha Rashid

Harmale Tiwana

Clyde Wilson

Affiliations

Soon will be listed here.

Abstract

Crohn's disease (CD) is an immune-mediated gastrointestinal inflammatory disease, which could arise from an interplay between genetic and environmental factors. Klebsiella microbes were suggested to have a vital role in the initiation and perpetuation of the disease through the mechanism of molecular mimicry. This proposition is based on the results of various studies where significantly elevated levels of antibodies against the whole bacteria or preparations from Klebsiella microbes and antibodies to collagen types I, III, IV, and V were detected in patients with CD and patients with ankylosing spondylitis (AS). Molecular similarities were found between Klebsiella nitrogenase and HLA-B27 genetic markers and between Klebsiella pullulanase and collagen fibers types I, III, and IV. Furthermore, significantly positive correlations and cross-reactivity binding activities were observed between anti-Klebsiella and anticollagen antibodies among patients with CD and AS. Early treatment of CD patients with anti-Klebsiella measures is proposed, which may involve the use of antibiotics and low starch diet together with other traditionally used immunomodulatory, immunosuppressive, or biologic agents.

Citing Articles

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients.

Dong Y, Wang P, Jiao J, Yang X, Chen M, Li J Front Cell Dev Biol. 2022; 10:861829.

PMID: 35399511 PMC: 8986158. DOI: 10.3389/fcell.2022.861829.

Mapping the relationships between inflammatory bowel disease and comorbid diagnoses to identify disease associations.

Waljee A, Noureldin M, Berinstein J, Cohen-Mekelburg S, Wallace B, Cushing K Eur J Gastroenterol Hepatol. 2020; 32(10):1341-1347.

PMID: 32804850 PMC: 9639789. DOI: 10.1097/MEG.0000000000001869.

The C-Type Lectin Mincle: Clues for a Role in Crohn's Disease Adjuvant Reaction.

Te Velde A Front Immunol. 2017; 8:1304.

PMID: 29109721 PMC: 5660320. DOI: 10.3389/fimmu.2017.01304.

Ectopic colonization of oral bacteria in the intestine drives T1 cell induction and inflammation.

Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S Science. 2017; 358(6361):359-365.

PMID: 29051379 PMC: 5682622. DOI: 10.1126/science.aan4526.

Alterations of the Gut Microbiome in Hypertension.

Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C Front Cell Infect Microbiol. 2017; 7:381.

PMID: 28884091 PMC: 5573791. DOI: 10.3389/fcimb.2017.00381.

References

Stallmach A, Schuppan D, Riese H, Matthes H, Riecken E . Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology. 1992; 102(6):1920-9. DOI: 10.1016/0016-5085(92)90314-o. View

Eastmond C, Woodrow J . Discordance for ankylosing spondylitis in monozygotic twins. Ann Rheum Dis. 1977; 36(4):360-4. PMC: 1006698. DOI: 10.1136/ard.36.4.360. View

Cooper R, Fraser S, Sturrock R, Gemmell C . Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. Br Med J (Clin Res Ed). 1988; 296(6634):1432-4. PMC: 2545892. DOI: 10.1136/bmj.296.6634.1432. View

Ebringer R, Cooke D, Cawdell D, Cowling P, Ebringer A . Ankylosing spondylitis: klebsiella and HL-A B27. Rheumatol Rehabil. 1977; 16(3):190-6. DOI: 10.1093/rheumatology/16.3.190. View

Baeten D, Demetter P, Cuvelier C, Kruithof E, Van Damme N, De Vos M . Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol. 2002; 196(3):343-50. DOI: 10.1002/path.1044. View

Tiwana H, Wilson C, Walmsley R, Wakefield A, Smith M, Cox N . Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Rheumatol Int. 1997; 17(1):11-6. DOI: 10.1007/pl00006845. View

Leiper K, Morris A, Rhodes J . Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther. 2000; 14(6):801-6. DOI: 10.1046/j.1365-2036.2000.00753.x. View

Rioux K, Fedorak R . Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2006; 40(3):260-3. DOI: 10.1097/00004836-200603000-00019. View

Herrlinger K, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke J . Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol. 2006; 101(4):793-7. DOI: 10.1111/j.1572-0241.2005.00356.x. View

10.

Reveille J, Arnett F . Spondyloarthritis: update on pathogenesis and management. Am J Med. 2005; 118(6):592-603. DOI: 10.1016/j.amjmed.2005.01.001. View

11.

de Keyser F, Elewaut D, De Vos M, de Vlam K, Cuvelier C, Mielants H . Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am. 1999; 24(4):785-813, ix-x. DOI: 10.1016/s0889-857x(05)70042-9. View

12.

Taurog J, Richardson J, Croft J, Simmons W, Zhou M, Fernandez-Sueiro J . The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994; 180(6):2359-64. PMC: 2191772. DOI: 10.1084/jem.180.6.2359. View

13.

Podswiadek M, Punzi L, Stramare R, DInca R, Ferronato A, Lo Nigro A . [The prevalence of radiographic sacroiliitis in patients affected by inflammatory bowel disease with inflammatory low back pain]. Reumatismo. 2004; 56(2):110-3. DOI: 10.4081/reumatismo.2004.110. View

14.

Andersson R, Olaison G, Tysk C, Ekbom A . Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology. 2003; 124(1):40-6. DOI: 10.1053/gast.2003.50021. View

15.

Steer S, Jones H, Hibbert J, Kondeatis E, Vaughan R, Sanderson J . Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol. 2003; 30(3):518-22. View

16.

Hanauer S, Sandborn W, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130(2):323-33. DOI: 10.1053/j.gastro.2005.11.030. View

17.

Van Damme N, De Vos M, Baeten D, Demetter P, Mielants H, Verbruggen G . Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis. 2001; 60(5):495-9. PMC: 1753653. DOI: 10.1136/ard.60.5.495. View

18.

Travassos W, Cheifetz A . Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005; 8(3):187-196. DOI: 10.1007/s11938-005-0011-2. View

19.

Laukens D, Peeters H, Marichal D, Vander Cruyssen B, Mielants H, Elewaut D . CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis. 2004; 64(6):930-5. PMC: 1755516. DOI: 10.1136/ard.2004.028837. View

20.

Steinhart A, Feagan B, Wong C, Vandervoort M, Mikolainis S, Croitoru K . Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002; 123(1):33-40. DOI: 10.1053/gast.2002.34225. View